Overview

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and bortezomib may kill more tumor cells
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Bortezomib
Carboplatin
Gemcitabine